Mumbai, February 12 IIT Bombay and QR678, a company specializing in non-surgical and US/India-patented hair growth therapy, have entered into an agreement to develop next-generation skin treatments and regenerative healing therapies, according to a statement released on Thursday.
The research and development arm, TECCRO, of QR678, has signed the agreement with IIT Bombay to collaborate on advanced dermatology, trichology, regenerative medicine, and translational clinical research, QR678 stated in the statement.
This will further enable TECCRO to continue research on the QR678 platform at the IIT Bombay campus, leveraging shared access to advanced research infrastructure and clinical evaluation platforms.
"This collaboration represents a critical step in building a strong bridge between engineering innovation and clinical reality. Our long-term goal is ambitious yet clear: to eliminate baldness in India by 2050 through rigorous science, scalable therapeutics, and measurable patient outcomes," said Dr. Debraj Shome, Clinician Scientist and Research Mentor, TECCRO.
He added that this partnership will also strengthen the company's intellectual property pipeline led by India, enabling both institutions to file more patents from India and catalyze IP-driven enterprises.